1.8(top 20%)
impact factor
1.6K(top 10%)
papers
23.5K(top 10%)
citations
61(top 10%)
h-index
1.9(top 50%)
impact factor
2.0K
all documents
25.5K
doc citations
106(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost–effectivenessExpert Review of Pharmacoeconomics and Outcomes Research2012556
2KIDSCREEN-52 quality-of-life measure for children and adolescentsExpert Review of Pharmacoeconomics and Outcomes Research2005551
3Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdExpert Review of Pharmacoeconomics and Outcomes Research2008543
4A point of minimal important difference (MID): a critique of terminology and methodsExpert Review of Pharmacoeconomics and Outcomes Research2011465
5The truly remarkable universality of half a standard deviation: confirmation through another lookExpert Review of Pharmacoeconomics and Outcomes Research2004375
6Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomesExpert Review of Pharmacoeconomics and Outcomes Research2010336
7Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes researchExpert Review of Pharmacoeconomics and Outcomes Research2010325
8Economic burden of healthcare-associated infections: an American perspectiveExpert Review of Pharmacoeconomics and Outcomes Research2009260
9Globalization and healthcare: understanding health and medical tourismExpert Review of Pharmacoeconomics and Outcomes Research2006247
10Interpreting patient-reported outcome results: US FDA guidance and emerging methodsExpert Review of Pharmacoeconomics and Outcomes Research2011242
11Internet-delivered treatments with or without therapist input: does the therapist factor have implications for efficacy and cost?Expert Review of Pharmacoeconomics and Outcomes Research2007238
12The PedsQL™ as a pediatric patient-reported outcome: reliability and validity of the PedsQL™ Measurement Model in 25,000 childrenExpert Review of Pharmacoeconomics and Outcomes Research2005232
13The minimum clinically important difference for EQ-5D index: a critical reviewExpert Review of Pharmacoeconomics and Outcomes Research2014217
14Valuing citizen and patient preferences in health: recent developments in three types of best–worst scalingExpert Review of Pharmacoeconomics and Outcomes Research2010197
15Rating scales and Rasch measurementExpert Review of Pharmacoeconomics and Outcomes Research2011185
16Patient recall and recall bias of health state and health statusExpert Review of Pharmacoeconomics and Outcomes Research2004183
17Discrete choice experiments to measure consumer preferences for health and healthcareExpert Review of Pharmacoeconomics and Outcomes Research2002175
18Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergyExpert Review of Pharmacoeconomics and Outcomes Research2020151
19Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illnessExpert Review of Pharmacoeconomics and Outcomes Research2009147
20Half standard deviation estimate of the minimally important difference in HRQOL scores?Expert Review of Pharmacoeconomics and Outcomes Research2004143
21PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studiesExpert Review of Pharmacoeconomics and Outcomes Research2005143
22Cancer-related fatigue: prevalence, assessment and treatment strategiesExpert Review of Pharmacoeconomics and Outcomes Research2011142
23How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3)Expert Review of Pharmacoeconomics and Outcomes Research2016134
24How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3)Expert Review of Pharmacoeconomics and Outcomes Research2016133
25Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implicationsExpert Review of Pharmacoeconomics and Outcomes Research2010131
26Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevanceExpert Review of Pharmacoeconomics and Outcomes Research2009126
27Priority setting in health: origins, description and application of the Australian Assessing Cost–Effectiveness initiativeExpert Review of Pharmacoeconomics and Outcomes Research2008124
28Direct and indirect cost of managing alzheimer’s disease and related dementias in the United StatesExpert Review of Pharmacoeconomics and Outcomes Research2017120
293D-printing and the effect on medical costs: a new era?Expert Review of Pharmacoeconomics and Outcomes Research2016115
30Health-state utility values in breast cancerExpert Review of Pharmacoeconomics and Outcomes Research2010112
31Quality of life and burden in caregivers for patients with Parkinson’s disease: concepts, assessment and related factorsExpert Review of Pharmacoeconomics and Outcomes Research2012112
32Meta-analysis of rare and adverse event dataExpert Review of Pharmacoeconomics and Outcomes Research2002107
33Economic burden of chronic painExpert Review of Pharmacoeconomics and Outcomes Research2006106
34The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challengesExpert Review of Pharmacoeconomics and Outcomes Research2013101
35Patient preferences and healthcare outcomes: an ecological perspectiveExpert Review of Pharmacoeconomics and Outcomes Research2012100
36Conceptual and methodological advances in child-reported outcomes measurementExpert Review of Pharmacoeconomics and Outcomes Research201099
37Burden of skin diseasesExpert Review of Pharmacoeconomics and Outcomes Research200996
38Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT)Expert Review of Pharmacoeconomics and Outcomes Research201896
39The EQ-5D-5L Valuation study in ThailandExpert Review of Pharmacoeconomics and Outcomes Research201894
40Measuring and managing patient expectations for breast reconstruction: impact on quality of life and patient satisfactionExpert Review of Pharmacoeconomics and Outcomes Research201293
41Multiple chronic conditions and healthcare costs among adultsExpert Review of Pharmacoeconomics and Outcomes Research201593
42Health utility estimationExpert Review of Pharmacoeconomics and Outcomes Research200291
43Quantifying stochastic uncertainty and presenting results of cost-effectiveness analysesExpert Review of Pharmacoeconomics and Outcomes Research200189
44Quality of life in psoriasis patientsExpert Review of Pharmacoeconomics and Outcomes Research201488
45Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?Expert Review of Pharmacoeconomics and Outcomes Research201788
46Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTGExpert Review of Pharmacoeconomics and Outcomes Research201083
47Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic reviewExpert Review of Pharmacoeconomics and Outcomes Research201583
48Life expectancy and health expenditure evolution in Eastern Europe—DiD and DEA analysisExpert Review of Pharmacoeconomics and Outcomes Research201681
49How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3)Expert Review of Pharmacoeconomics and Outcomes Research201680
50Cognitive dysfunction and work productivity in major depressive disorderExpert Review of Pharmacoeconomics and Outcomes Research201679